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Abstract
Nosocomial infections have become a serious threat in our times and are getting more diffi-
cult to handle due to increasing development of resistances in bacteria. In this light, cold
atmospheric plasma (CAP), which is known to effectively inactivate microorganisms, may
be a promising alternative for application in the fields of dentistry and dermatology. CAPs
are partly ionised gases, which operate at low temperature and are composed of electrons,
ions, excited atoms and molecules, reactive oxygen and nitrogen species. In this study, the
effect of CAP generated from ambient air was investigated against Enterococcus faecalis,
grown on agar plates or as biofilms cultured for up to 72 h. CAP reduced the colony forming
units (CFU) on agar plates by > 7 log10 steps. Treatment of 24 h old biofilms of E. faecalis
resulted in CFU-reductions by� 3 log10 steps after CAP treatment for 5 min and by� 5
log10 steps after CAP treatment for 10 min. In biofilm experiments, chlorhexidine (CHX) and
UVC radiation served as positive controls and were only slightly more effective than CAP.
There was no damage of cytoplasmic membranes upon CAP treatment as shown by spec-
trometric measurements for release of nucleic acids. Thus, membrane damage seems not
to be the primary mechanism of action for CAP towards E. faecalis. Overall, CAP showed
pronounced antimicrobial efficacy against E. faecalis on agar plates as well as in biofilms
similar to positive controls CHX or UVC.
Introduction
Within the last 10 years, treatment of infectious diseases such as wound infections of the skin
and the mucous membranes has become increasingly more complicated and ineffective due to
the emergence of drug-resistant bacteria. In the 2016 Review on Antimicrobial Resistance, an
alarming scenario was built up presaging that by 2050 10 million people could die per year
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caused by multidrug-resistant bacteria [1]. Eradication of multi-resistant superbugs like the
so-called “ESKAPE”-pathogens is one of the major clinical challenges of the twenty-first cen-
tury [2]. One of the pathogens being often causative for nosocomial infections like catheter-
associated urinary tract infections is the Gram-positive coccus Enterococcus faecalis [3]. E. fae-
calis combines many virulence factors like intrinsic resistances to several classes of antibiotics
[4]. Furthermore, it is known for its ability to gain resistance in a relatively short amount of
time [5]. In addition, E. faecalis is able to form biofilms on both, inanimate and living surfaces
which raises tolerance and decreases susceptibility against environmental influences or antimi-
crobial measures [6, 7].
In general, bacterial biofilms are found on natural surfaces as well as on artificial ones like
inside of catheters or on other implants [8]. Bacteria in such a sessile biofilm-mode are known
to be much more tolerant towards antimicrobial approaches than their planktonic counter-
parts [9]. A primary mechanism for this enhanced tolerance is the extracellular polymeric sub-
stance (EPS) which bacteria are embedded in and which can act as a diffusion barrier for
antimicrobial agents [10].
Therefore, novel treatment modalities that are capable of killing pathogens in biofilms with
less or even no risk of inducing resistances are desperately needed [11]. Accordingly, already
in 2011 a review published by Karen Bush et al. in Nature Reviews Microbiology had pointed
out that „investigation of novel non-antibiotic approaches for the prevention of and protection
against infectious diseases should be encouraged and that such approaches must be high-prior-
ity research” [12]. Therefore, new approaches must be developed that are capable of eliminat-
ing bacteria successfully, independently of their resistance patterns [13]. In this light, a novel
therapeutic option may be cold atmospheric plasma (CAP), which is a highly innovative tech-
nology due to the point that no resistances have been induced in bacteria against CAP so far
[14]. CAPs are partly ionized gases (with a typical ionization fraction of one ion or electron
per a billion neutral atoms or molecules) producing a reactive mix by interacting with the sur-
rounding air and being composed of electrons, ions, neutrons, excited atoms and molecules,
reactive oxygen and nitrogen species, and UV light [15]. Depending on the respective plasma
source technology, the carrier gas (here: ambient air), the plasma operating parameters and
the set-up modalities (like transportation mode, volume etc.), the composition as well as the
concentrations of the produced plasma species vary. This means, that CAPs can be “designed”
to a certain extent and that different compositions of reactive species can be produced by
changing input parameters such as carrier gas, voltage, frequency etc. [16].
CAPs are known to effectively inactivate bacteria and fungi (independent of their resistance
profiles towards conventional antimicrobials as well as on different surfaces and in biofilms),
spores and viruses [17, 18]. Furthermore, it could be shown that CAP doses can be found
where pathogens can be inactivated without mammalian tissues being harmed or without
changing the characteristics of the respective materials that bacteria are attached to [19, 20].
Due to these results and, moreover, as CAP operate at low temperatures (5–10˚C above room
temperature only), various applications in hygiene (e.g. sterilization of medical equipment,
hand disinfection etc.) and in clinical practice (e.g. treatment of infected wounds) are currently
under investigation in the plasma medicine community [21, 22].
Consequently, plasma medicine–an evolving research field investigating CAP and their
potential application in hygiene and medicine–has attracted a lot of interest in the past few
years. However, the actual mechanisms of the antimicrobial action of CAP are still mostly
unknown [23]. Furthermore, the antimicrobial efficacy of CAP against microbial biofilms is
still not sufficiently explored and only very few studies have been performed up to this point
[24–28]. Recently, our group showed that DNA damage seems not to be the primary mecha-
nism of bacterial cell death upon CAP treatment because Deinococcus radiodurans, which is
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known to have a very efficient DNA repair mechanism, can easily be killed by CAP [29],
whereas this bacterium survives ionizing radiation up to 5000 Gy without being harmed [30].
Taking into consideration that the external structures like cell walls and cytoplasmic mem-
branes most likely are destroyed before nucleic acids can be targeted, it seems reasonable that
these outer cellular structures may be first-line targets of CAP [31].
Therefore, the aims of this study were (1) to investigate the antimicrobial efficacy of CAP
with a novel surface micro-discharge (SMD) technology in a thin-film design towards E. faeca-
lis in planktonic cultures as well as in biofilms and (2) to evaluate whether CAP treatment
leads to cytoplasmic membrane damage as measured by leakage of cytoplasmic components
upon treatment.
Material and methods
Thin-film surface micro-discharge plasma source
In this study, a CAP plasma source prototype was used under ambient conditions (natural
fluctuation room with�21˚C). This prototype consists of one surface micro-discharge (SMD)
plasma source with thin-film design composed of an insulator plate made out of Al2O3 (thick-
ness 0.25 mm), a high voltage (= HV) electrode coated with Cu and Sn (thickness of 3.0 μm
and 1.0 μm, respectively) electrode and a structured electrode, meaning an electrically
grounded stainless-steel mesh electrode (basic material 1.4310, thickness 0.5 mm, square-
shape structured). The novel thin-film design is the result of further development of the SMD
plasma source described by Shimizu et al. [32]. The new design provides a technique that can
be manufactured in series with minimized height. Therefore, the plasma source only needs a
minimum of power that allows for battery-driven operation. The plasma is produced homoge-
nously on the structured electrode by applying high sinusoidal AC voltage of 3.5 kVPP at a fre-
quency of 4.0 kHz between the HV electrode and the structured electrode. In contrast to
DBD-technology (dielectric-barrier-discharge), there is no current through the treatment
object. The power consumption of this plasma source is about 0.5 to 1 W (depending on the
surrounding humidity) and contains mainly reactive oxygen species.
The plasma source (composed of HV electrode, insulator plate and structured electrode) itself
is embedded in a plastic case to ensure safe and easy handling during the experimental proce-
dures (Fig 1). The size of the plasma source including the outer rim is 39.5 mm x 39.5 mm. The
size of the plasma production area on the structured electrode is 29.5 mm x 29.5 mm. A spacer
(inner height 10 mm, inner diameter 40 mm, outer diameter 50 mm, treatment area 12.56 cm2,
material Polytetrafluorethylene) which is attached to the plasma source and surrounds the struc-
tured electrode, allows the formation of a (semi-) closed volume of 126 mL (between plasma
source and biological sample) so that the produced plasma species are confined inside.
The plasma source is placed above the sample. The transportation of the generated plasma
species to the sample is carried out by diffusion and thermal convection. Depending on the
experiments, treatment periods ranged between 1 min and 10 min in this study.
Fig 1. Schematic view of the plasma source prototype with surface micro-discharge-technology (SMD) in thin-
film design. Ambient air is used and an area of interest of 12.56 cm2 can be treated.
https://doi.org/10.1371/journal.pone.0223925.g001
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Bacterial culture
Enterococcus faecalis (DSM 2570, ATCC 29212) was obtained from the DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) to be
used for these experiments. E. faecalis was maintained on Mu¨ller-Hinton agar plates. For inoc-
ulation, one single colony was picked, suspended in 5 ml Brain Heart Infusion broth (BHI;
Sigma-Aldrich, St. Louis, MO, USA) and incubated over-night at 37˚C on an orbital shaker
(180 rpm). Afterwards, cultures were harvested by centrifugation (10 min, 3000 rpm;
Table centrifuge Universal 320R, Hettich Germany), resuspended in phosphate-buffered saline
(PBS; Dulbecco’s Phosphate Buffered Saline, Sigma-Aldrich, St. Louis, MO, USA) and the opti-
cal density (OD) was measured at 600 nm by means of a spectrophotometer (SPECORD 50
Plus, Analytik Jena, Jena, Germany). Bacterial suspensions were adjusted to an OD of 0.6 for
planktonic experiments or to an OD of 0.13 for biofilm formation, respectively.
CAP treatment towards planktonic bacteria on agar plates
E. faecalis suspensions were used at an OD of 0.6. 100 μL of bacterial suspension were spread
on Mu¨ller-Hinton agar plates and then exposed to CAP treatment (for 1, 3, 5 or 10 min), while
the spacer mentioned above ensured a distance of 10 mm between plasma source and samples.
After subsequent incubation of the agar plates at 37˚C for 24 h, colony forming units (CFUs)
were evaluated. The area of interest was calculated based on the inner diameter of the spacer
(40 mm) related to the whole area of the agar plates. For computation of log10-reduction rates,
CFUs of serial dilutions of the original bacterial suspensions at OD = 0.6 were evaluated.
Biofilm formation
E. faecalis biofilms were formed as it has been described earlier in detail [33, 34]. Briefly, over-
night cultures of E. faecalis (OD = 0.13) were harvested by centrifugation and resuspended in
the complete saliva (CS) broth originally described by Pratten et al. [35], which was modified
by adding 0.1% (w/v) sucrose [33, 34]. 2 mL of this bacterial suspension in CS broth were
mixed with 1 mL fetal calf serum (FCS; Pan-Biotech GmbH, Aidenbach, Germany) and added
to sterile polystyrene petri dishes (35 mm x 10 mm; PrimariaTM Easy Grip Cell Culture Dish,
Corning, NY, USA). Biofilms were incubated at 37˚C under aerobic conditions without shak-
ing for 24, 48 or 72 h, respectively. For biofilms cultured for more than 24 h, growth medium
was changed every 24 h.
After the respective culture period, growth medium was carefully discarded with a pipette.
Afterwards, the biofilms were treated with CAP for 1, 3, 5 or 10 min, respectively. For biofilm
inactivation a spacer adjusted to a height of 20 mm was placed over the polystyrene petri dish
and the CAP plasma source was placed on top of it. The biofilm was removed by scratching
the biofilm from the bottom of the plastic well as well as by pipetting up and down repeatedly.
Removal of all attached cells was checked by using light microscopic observation of the bottom
of each petri dish. For separation of aggregated bacteria, the tubes were vortexed for 10 s and
placed in an ultrasonic (35 kHz) water bath chamber (USR 30 H, Merck Eurolab GmbH, Graf-
ing, Germany) for 10 min. Subsequently, serial tenfold dilutions were prepared (up to 10−16)
and aliquots (3x 20 μL) were plated on Mu¨ller-Hinton agar plates according to the method
described by Miles et al. [36]. CFU were evaluated after aerobic incubation for 24 h at 37˚C.
UVC radiation and treatment with chlorhexidine digluconate (CHX; Sigma-Aldrich,
St. Louis, MO, USA) were used as positive controls. UVC radiation was performed with a
DNA crosslinker operating at 254 nm (Biometra GmbH, Go¨ttingen, Germany; radiation
doses: 0.005 J/cm2, 0.195 J/cm2 or 0.26 J/cm2). CHX was used at concentrations of 0.2% or 2%
and incubation was carried out for 5 min.
CAP against E. faecalis in vitro
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Spectroscopic measurements for release of nucleic acids upon CAP
treatment
To evaluate whether CAP treatment leads to damage of cytoplasmic membranes, release of
nucleic acids from the cytoplasm was measured spectroscopically at 260 nm as described earlier
[37, 38]. Biofilms were cultured as described above and treated with CAP for 5 or 10 min, respec-
tively. As a positive control, the biofilms were scraped, resuspended in PBS and incubated with
100 μL lysozyme (40,000 units/mg; Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37˚C.
Then, 100 μL Proteinase K (7.0–14.0 units/mg; Sigma-Aldrich, St. Louis, MO, USA) and 200 μL
1% sodium dodecyl sulfate (Carl Roth GmbH + Co. KG, Karlsruhe, Germany) were added and
incubated for another 30 min at 37˚C. The biofilms were brought to suspension in 1 mL PBS
and transferred to 1.5 mL Eppendorf tubes. After sonication in an ultrasonic water bath chamber
(Sonorex Super RK 102 H; 35kHz) for 10 min, the tubes were centrifuged (13.000 rpm; 5 min)
and the supernatants were collected and evaluated for nucleic acid release by assessing the OD at
260 nm with a NanoDropTM 2000 spectrophotometer (PEQLAB, Erlangen, Germany).
Data analysis
CFU results are shown as medians, 1st and 3rd quartiles and were calculated using SPSS for
Windows, v. 25 (SPSS Inc., Chicago, IL, USA) from the values of at least six independent
experiments. In the figures, horizontal solid and dashed lines show 3 and 5 log10 steps reduc-
tion of CFU compared to the untreated control (7.3 x 1010 CFU in median). Medians on or
below these lines mean a bacterial reduction by 3 log10 (�99.9%) or by 5 log10 (�99.999%) or
higher, respectively. According to the guidelines of infection control this means a biologically
relevant antimicrobial activity or a disinfectant effect, respectively [39]. Results from spectro-
scopic measurements are depicted as medians, minima and maxima, and were calculated by
SPSS from the values of three independent experiments at least.
Results
Antimicrobial assay towards planktonic E. faecalis on agar plates
Firstly, we investigated the antimicrobial efficacy of CAP towards planktonic E. faecalis on
agar plates (Fig 2). The untreated controls (no CAP) exhibited 7.3 x 1010 CFU in median. CAP
treatment for 1 min led to a CFU reduction of� 7 log10 steps. Longer CAP treatment periods
of 3, 5 or 10 min did further increase the killing efficacy (reductions of� 8 log10 steps (3 or 5
min) or� 9 log10 steps (10 min), respectively).
Antimicrobial assay towards E. faecalis biofilms cultured for 24 h
Secondly the antimicrobial efficacy of this new CAP device was evaluated towards E. faecalis
growing as 24 h old biofilms (Fig 3). Untreated biofilms contained 1.9 x 1014 CFU in median.
CAP treatment for 5 min showed a CFU-reduction by� 3 log10 steps, while CAP treatment
for 10 min resulted in a reduction by� 5 log10 steps. Reductions for 1 and 3 min of CAP treat-
ment were < 3 log10 steps.
In addition, CHX and UVC radiation were evaluated as positive controls compared to the
CAP treatment efficacy towards E. faecalis (Fig 4). Again, E. faecalis biofilms were cultured for
24 h. CHX 0.2% led to a CFU reduction of�3 log10 steps after 5 min while CHX 2% resulted
in reduction by� 9 log10 steps below the detection limit. A UVC radiation dose of 0.005 J/cm
2
reduced the CFU by� 5 log10 steps. Higher doses of 0.195 J/cm
2 or 0.26 J/cm2 reduced CFU
by� 9 log10 steps below the detection limit. Overall UVC radiation as a contact-free
CAP against E. faecalis in vitro
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Fig 2. Antimicrobial assay towards planktonic E. faecalis on agar plates. CAP was performed for different treatment
periods. Surviving colonies were counted 24 h later. All results are depicted as medians, 1st and 3rd quartiles from six
independent experiments in duplicates on a log10-scaled ordinate. Bars show the reductions of CFU in a log10 scale in
comparison to untreated controls. Solid and dashed lines exhibit 3 log10 steps (99.9%) or 5 log10 steps reduction
(99.999%) of CFU, respectively. (n = 6; untreated controls exhibited 7.3 x 1010 CFU in median).
https://doi.org/10.1371/journal.pone.0223925.g002
Fig 3. Antimicrobial efficacy of CAP towards E. faecalis biofilms cultured for 24 h. CAP was performed for
different treatment periods towards biofilms cultured for 24 h. All results are depicted as medians, 1st and 3rd quartiles
from six independent experiments in duplicates on a log10-scaled ordinate. Bars show the reductions of CFU in a log10
scale in comparison to untreated controls. Solid and dashed lines exhibit 3 log10 steps (99.9%) or 5 log10 reduction
(99.999%) of CFU, respectively. (n = 6; untreated controls exhibited 7.3 x 1010 CFU in median).
https://doi.org/10.1371/journal.pone.0223925.g003
CAP against E. faecalis in vitro
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application led to higher reduction of CFU in a dose-dependent manner compared to CAP,
whereas the efficacy of CHX 0.2% treatment was similar to the CAP treatment.
Antimicrobial assay towards E. faecalis biofilms cultured for 48 h or 72 h
The previous results emphasize to investigate the antimicrobial efficacy of CAP towards bio-
films cultured for longer times like 48 h or 72 h (mature biofilms). Table 1 shows the results of
CAP treatment, CHX or UVC radiation towards biofilms cultured for 48 h or 72 h. The CFU
of E. faecalis were reduced by� 5 log10 steps by a CAP treatment of 10 min for both 48 h and
72 h old biofilms. CHX 2% led to CFU-reductions by� 6 log10 steps irrespective of the culture
period, while CHX 0.2% reduced the CFU by�4 log10 steps in 48 h biofilms and by�3 log10
steps in 72 h biofilms. UVC radiation led to reductions by�6 log10 steps for radiation doses of
0.065 J/cm2, 0.13 J/cm2 or 0.26 J/cm2.
Spectroscopic measurements for release of nucleic acids upon CAP
treatment
For assessing damage of cytoplasmic membranes upon CAP treatment, the release of nucleic
acids from the cytoplasm was measured spectroscopically at 260 nm. Results are depicted in
Fig 5. While the positive control showed a clear increase in median OD (0.5525) as compared
to untreated controls (median OD 0.012), CAP treatment showed no increases in OD (median
OD< 0.1), irrespective whether treatment was for 5 or 10 min. These results imply that the
course of inactivation does not include direct cell lysis during CAP treatment.
Fig 4. Antimicrobial efficacy of positive controls CHX and UVC radiation towards E. faecalis biofilms cultured
for 24 h. Biofilms were incubated with CHX (0.2% or 2%) for 5 min. UVC radiation was performed applying distinct
radiation doses (0.005 J/cm2, 0.065 J/cm2, 0.13 J/cm2 or 0.26 J/cm2). All results are depicted as medians, 1st and 3rd
quartiles from six independent experiments in duplicates on a log10-scaled ordinate. Bars show the reductions of CFU
in a log10 scale in comparison to untreated controls. Solid and dashed lines exhibit 3 log10 steps (99.9%) or 5 log10
reduction (99.999%) of CFU, respectively. (n = 6; untreated controls exhibited 7.3 x 1010 CFU in median).
https://doi.org/10.1371/journal.pone.0223925.g004
CAP against E. faecalis in vitro
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Discussion
Cold atmospheric plasma generates a wide variety of reactive species in form of e.g. ozone,
reactive oxygen species and nitrogen dioxide which are the main source for its antimicrobial
efficacy [40]. These CAP-derived reactive species are generated by a contact-free manner and
are also not highly specialized to different bacterial genera or strains. This is a major advantage
in comparison to antibiotics which target only specific structures according to the so-called
key-lock principle [41]. That is the crucial aspect in which CAP could be named superior to
common antibiotics and antiseptics, which are countered by bacteria through specific mecha-
nisms of resistance [42]. Up to now, the risk of bacteria developing resistance against CAP is
considered minor even after multiple sublethal treatments due to the point that no specific
bacterial target is in focus but rather multiple targets [14].
In general, two approaches are in the focus with regard to CAP. The indirect method is
using an agent to submit the effective particles as it is used in plasma jets or SMD technology
[43–45]. Such a device consists of an outer electrode and an inner electrode and the gas is
pumped through and thereby ionized. This method allows a longer distance between the
affected area and the CAP device [46, 47]. Such devices were already used for treating skin dis-
eases to reduce the microbial colonization of the infected tissue. SMD technology as it is used
in this study is based on the same approach as the plasma jet, but a constant flow of externally
applied gas is not needed because it uses ambient air as its carrier gas. The direct method sub-
mits the effective particle directly to the surface of the treated object (e.g. patient), that means
the patient operates as the counter-electrode during treatment. Limitation is the distance
between operating tool and the object of treatment [48]. Joaquin et al. used an atmospheric
plasma jet to effectively inactivate a biofilm produced by Chromobacterium violaceum [49].
Laroussi et al. reviewed an atmospheric plasma jet and distinct discharge plasma sources to
inactivate different bacterial species [50]. Depending on the chemical composition of reactive
species generated by CAP, it was demonstrated that high levels of oxygen improved the anti-
bacterial efficacy, e.g. towards Escherichia coli [51]. Furthermore, inactivation of extracellular
virulence factors by CAP is also possible. Ziuzina et al. showed that inactivation of different
virulence factors like pyocyanin or other quorum sensing molecules in Pseudomonas aerugi-
nosa was successful [52]. In addition, the cytotoxic effects of pyocyanin were as well effectively
reduced by CAP. So far, different studies were performed with plasma devices like plasma jets
Table 1. Results from antimicrobial assay towards E. faecalis biofilms cultured for 48 h or 72 h.
Biofilm age
Treatment Concentration / radiation dose Treatment period 48 h 72 h
CAP n/a 1 min 1.8 1.7
n/a 3 min 1.8 2.0
n/a 5 min 2.6 2.4
n/a 10 min 5.7 4.9
CHX 0.2% 5 min 4.1 3.9
2% 5 min � 6 � 6
UVC radiation 0.065 J/cm2 n/a � 6 -
0.13 J/cm2 n/a � 6 -
0.26 J/cm2 n/a � 6 -
n/a = not applicable
- = not determined
This table shows the results from antimicrobial assay towards E. faecalis biofilms cultured for 48 h or 72 h. Values show log10 reductions
https://doi.org/10.1371/journal.pone.0223925.t001
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and direct dielectric cold plasma devices, to affect E. faecalis, as organism of the ESKAPE path-
ogen group [53, 54]. Modic et al. showed the efficacy of CAP against biofilms formed by Staph-
ylococcus aureus and Pseudomonas aeruginosa, which also belong to the ESKAPE pathogen
group [55]. Moreover, other studies also demonstrated the antibacterial efficacy of cold plas-
mas against ESKAPE pathogens [56, 57]. Application of CAP against E. faecalis yielded prom-
ising effects, also in other environments (like in root canal treatment) when compared to
photodynamic inactivation of microorganisms [58, 59]. Du et al. treated monospecies biofilms
of E. faecalis with CAP [60]. They showed that the antibacterial efficacy was highest within the
first 3 min and decreases after 10 and 30 min. In addition, they were able to confirm that the
antibacterial efficacy of their plasma device was similar to that of 2% CHX [60]. Therefore, our
study model is in accordance with already published papers, that E. faecalis grown as a biofilm
can be successfully inactivated within a treatment period of up to 10 min. It is important to
clarify that no effects on host cells and tissues occur with the use of the SMD device, since it
has already been shown that CAP generated from this SMD technology exhibited no mutage-
nicity or toxicity against host cells and tissues in vitro or ex vivo [61, 62].
The first goal of this study was to prove that a new CAP device can kill E. faecalis seeded as
planktonic cultures on agar plates. Here, a CFU-reduction of> 7 log10 steps was found after 1
min of CAP treatment, while longer treatment periods showed even higher reductions of
CFU. Based on these results, the next experiments were focused on biofilms formed by E. fae-
calis. Bacteria in biofilms are generally more tolerant against antimicrobial approaches, which
poses health risks in all fields of medicine, including dentistry [9]. Accordingly, E. faecalis bio-
films are known to be problematic to handle in the field of endodontics and have been subject
to different studies in the past [24, 63]. In the present study, biofilms of E. faecalis were cul-
tured for different periods of time to investigate potential effects of the biofilm culture period
on the antimicrobial efficacy of this CAP device. In 24 h biofilms, CAP treatment showed
CFU-reductions by� 3 log10 after 5 min and� 5 log10 after 10 min. CFU-reductions by� 5
log10 steps could also be achieved in 48 h and 72 h old biofilms when they were subjected to
Fig 5. Spectroscopic measurements for release of nucleic acids upon CAP treatment. OD medians, minima and
maxima of the supernatants of untreated biofilms (UC) or biofilms treated with positive control (lysozyme treatment
followed by Proteinase K digestion, (PC)) or CAP, as measured at 260 nm for release of nucleic acids. For CAP,
samples were measured either 5 or 20 min after being treated with CAP for 5 or 10 min or left untreated (UC’). n = 6.
https://doi.org/10.1371/journal.pone.0223925.g005
CAP against E. faecalis in vitro
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CAP treatment for 10 min. Herbst et al. infected 50 root canals with E. faecalis and used differ-
ent methods for antimicrobial treatment CFU [63]. The most effective methods were CHX
combined with CAP followed by CHX and CAP alone. The results showed that the efficacy
against E. faecalis was in the same range for CHX and CAP. Li et al. cultured biofilms of E. fae-
calis in root canals over 3 weeks and subjected them to CAP or CHX [24]. The results again
showed similar results between CHX and CAP. After a treatment (either with CAP or CHX)
for 12 min, the number of CFU was under the limit of detection. As mentioned above, the two
studies by Herbst et al. and Li et al. showed that CAP was as effective as CHX for killing of E.
faecalis biofilms. Here, CHX was slightly more effective irrespective of biofilm culture period.
However, it must be considered that CAP works without any physical contact and may there-
fore be superior to CHX in terms of handling and application. In this instance, it is also note-
worthy that the CAP device used in this study works with ambient air as a carrier gas in
contrast to other plasma devices, which mostly use Argon or Helium as a carrier gas [62].
In the third part of this study, we tried to get first insights into the antimicrobial mechanism
of CAP. Up to this point the mechanism of different CAP treatments were investigated for
Escherichia coli and Staphylococcus aureus with different results [64]. Han et al. showed that
both bacterial strains reacted in different ways to the exposition of CAP. E. coli was inactivated
by cell leakage due to the damage of the lipopolysaccharides in the outer cell membrane and
the thin peptidoglycan layers of the cell wall of Gram-negative bacteria. S. aureus on the other
hand contains very thick peptidoglycan layers as Gram-positive bacteria compared to E. coli.
Here, damage of intracellular components was observed, but the cell wall was still intact [64].
Therefore, we aimed to determine whether damage of cytoplasmic membranes may be the pri-
mary antimicrobial mechanism of CAP generated by SMD technology. For this purpose,
release of nucleic acids upon treatment was measured spectroscopically at 260 nm [37]. The
results showed that there was no increase in OD upon treatment with CAP, even after a dura-
tion of 5 or 20 min between CAP treatment and measurement. Therefore, the antimicrobial
effects of CAP may not be due to direct damage of cytoplasmic membranes and the subsequent
release of cytoplasmic constituents. That indicates that the generated reactive species may
rather lead to a malfunction than to a disruption of the cell membrane by Gram-positive bacte-
rial species. Recently, our group could demonstrate that direct damage of DNA seems not to
be the primary mechanism of action of CAP due to the point that D. radiodurans could be
eradicated efficiently by CAP [29]. D. radiodurans contains a very efficient DNA repair mecha-
nism to survive hundreds of DNA double strand breaks by reassembling these accurately
before initiation of the next cycle of cell division [65]. The effective inactivation of this bacte-
rium by CAP indicates that bacterial targets other than DNA are damaged by CAP, since D.
radiodurans can repair DNA damage more efficiently than E. faecalis or other bacteria [66].
Recently, Arjunan et al. summarized the current knowledge about the interactions of reactive
oxygen species and reactive nitrogen species with DNA and its components generated by CAP
devices, and reported that strand breaks in DNA or peroxynitrite oxidation of nucleotides take
place [67]. Overall, we could show that this new CAP device has a pronounced antimicrobial
efficacy against E. faecalis on agar plates as well as in biofilms and we could give insight into
the mechanisms of action of CAP in terms of not releasing DNA and therefore not the possible
problems induced by DNA damage. However, further studies on the antimicrobial mecha-
nisms of CAP are essential for deeper understanding the effects of CAP.
Conclusions
In this study cold atmospheric plasma was used to achieve an antibacterial reduction of
>99.9% of Enterococcus faecalis growing as biofilms similarly to the effect of 0.2%
CAP against E. faecalis in vitro
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chlorhexidine. The superiority of CAP is the fact that it operates completely contact free. Fur-
thermore, this study demonstrated that release of cytoplasmic components due to direct dam-
age of the bacterial cell wall or membrane seems not to be the primary mechanism of
inactivation of E. faecalis by CAP.
Supporting information
S1 File. Data sets necessary to replicate study findings for Fig 2, Fig 3, Fig 4, Fig 5 and
Table 1 are listed.
(DOCX)
Acknowledgments
This study was funded by the grant “BayMed: 41-6618c/272/1-MED-1507-0004” (Bayern
Innovativ GmbH, Germany). Furthermore, Fabian Cieplik thanks for funding by the Univer-
sity Medical Center Regensburg (ReForM B program) and the Deutsche Forschungsge-
meinschaft (DFG, German Research Foundation; grant CI 263/1-3). Denise Muehler is
gratefully acknowledged for her valuable help with the DNA release experiments.
Author Contributions
Conceptualization: Fabian Cieplik, Tim Maisch, Julia L. Zimmermann.
Data curation: Felix Theinkom.
Formal analysis: Karl-Anton Hiller.
Funding acquisition: Sylvia Cantzler, Julia L. Zimmermann.
Investigation: Felix Theinkom, Larissa Singer, Fabian Cieplik, Tim Maisch.
Methodology: Felix Theinkom, Larissa Singer, Sylvia Cantzler, Hannes Weilemann, Maximil-
ian Cantzler, Karl-Anton Hiller.
Project administration: Sylvia Cantzler, Hannes Weilemann, Maximilian Cantzler, Tim
Maisch, Julia L. Zimmermann.
Resources: Hannes Weilemann, Maximilian Cantzler.
Software: Hannes Weilemann, Maximilian Cantzler, Karl-Anton Hiller.
Supervision: Fabian Cieplik, Karl-Anton Hiller, Tim Maisch, Julia L. Zimmermann.
Validation: Karl-Anton Hiller, Tim Maisch, Julia L. Zimmermann.
Writing – original draft: Felix Theinkom, Larissa Singer, Tim Maisch, Julia L. Zimmermann.
Writing – review & editing: Fabian Cieplik, Sylvia Cantzler, Karl-Anton Hiller, Tim Maisch,
Julia L. Zimmermann.
References
1. O’Neill Jea. Tackling drug-resistant infections globally: final report and recommendations. 2016.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no
ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(1):1–12.
Epub 2008/11/28. https://doi.org/10.1086/595011 PMID: 19035777.
3. Guiton PS, Hung CS, Hancock LE, Caparon MG, Hultgren SJ. Enterococcal biofilm formation and viru-
lence in an optimized murine model of foreign body-associated urinary tract infections. Infect Immun.
CAP against E. faecalis in vitro
PLOS ONE | https://doi.org/10.1371/journal.pone.0223925 November 26, 2019 11 / 15
2010; 78(10):4166–75. Epub 2010/08/11. https://doi.org/10.1128/IAI.00711-10 PMID: 20696830;
PubMed Central PMCID: PMC2950371.
4. Kajihara T, Nakamura S, Iwanaga N, Oshima K, Hirano K, Miyazaki T, et al. Comparative efficacies of
daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis. J Infect Chemother.
2017; 23(7):498–501. Epub 2017/01/22. https://doi.org/10.1016/j.jiac.2016.12.002 PMID: 28108098.
5. Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolates of Entero-
coccus species. Indian J Med Res. 2013; 137(5):981–5. Epub 2013/06/14. PMID: 23760387; PubMed
Central PMCID: PMC3734693.
6. Duggan JM, Sedgley CM. Biofilm formation of oral and endodontic Enterococcus faecalis. J Endod.
2007; 33(7):815–8. Epub 2007/09/07. https://doi.org/10.1016/j.joen.2007.02.016 PMID: 17804318.
7. Mohamed JA, Huang DB. Biofilm formation by enterococci. J Med Microbiol. 2007; 56(Pt 12):1581–8.
Epub 2007/11/24. https://doi.org/10.1099/jmm.0.47331-0 PMID: 18033823.
8. Ch’ng JH, Chong KKL, Lam LN, Wong JJ, Kline KA. Biofilm-associated infection by enterococci. Nat
Rev Microbiol. 2018. Epub 2018/10/20. https://doi.org/10.1038/s41579-018-0107-z PMID: 30337708.
9. Marsh PD, Bradshaw DJ. Dental plaque as a biofilm. J Ind Microbiol. 1995; 15(3):169–75. Epub 1995/
09/01. 10.1007/bf01569822 PMID: 8519474.
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001; 358(9276):135–8.
Epub 2001/07/21. 10.1016/s0140-6736(01)05321-1 PMID: 11463434.
11. Cieplik F, Deng D, Crielaard W, Buchalla W, Hellwig E, Al-Ahmad A, et al. Antimicrobial photodynamic
therapy—what we know and what we don’t. Crit Rev Microbiol. 2018:1–19. Epub 2018/05/12. 10.1080/
1040841X.2018.1467876 PMID: 29749263.
12. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al. Tackling antibiotic resistance.
Nat Rev Microbiol. 2011; 9(12):894–6. Epub 2011/11/04. 10.1038/nrmicro2693 PMID: 22048738;
PubMed Central PMCID: PMC4206945.
13. Sˇ imončicova´ J, Krysˇtofova´ S., Medvecka´ V. et al. Technical applications of plasma treatments: current
state and perspectives. Appl Microbiol Biotechnol. 2019. https://doi.org/10.1007/s00253-019-09877-x.
14. Matthes R, Assadian O, Kramer A. Repeated applications of cold atmospheric pressure plasma does
not induce resistance in Staphylococcus aureus embedded in biofilms. GMS Hyg Infect Control. 2014;
9(3):Doc17. Epub 2014/10/07. 10.3205/dgkh000237 PMID: 25285261; PubMed Central PMCID:
PMC4184041.
15. Maisch T, Shimizu T, Isbary G, Heinlin J, Karrer S, Klampfl TG, et al. Contact-free inactivation of Can-
dida albicans biofilms by cold atmospheric air plasma. Appl Environ Microbiol. 2012; 78(12):4242–7.
Epub 2012/04/03. 10.1128/AEM.07235-11 PMID: 22467505; PubMed Central PMCID: PMC3370520.
16. Duan Y, Huang C, Yu QS. Cold plasma brush generated at atmospheric pressure. Rev Sci Instrum.
2007; 78(1):015104. Epub 2007/05/17. 10.1063/1.2409624 PMID: 17503943.
17. Weiss M, Daeschlein G, Kramer A, Burchardt M, Brucker S, Wallwiener D, et al. Virucide properties of
cold atmospheric plasma for future clinical applications. J Med Virol. 2017; 89(6):952–9. Epub 2016/10/
04. 10.1002/jmv.24701 PMID: 27696466.
18. Heinlin J, Maisch T, Zimmermann JL, Shimizu T, Holzmann T, Simon M, et al. Contact-free inactivation
of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment. Future Micro-
biol. 2013; 8(9):1097–106. Epub 2013/09/12. 10.2217/fmb.13.86 PMID: 24020738.
19. Maisch T, Shimizu T, Li YF, Heinlin J, Karrer S, Morfill G, et al. Decolonisation of MRSA, S. aureus and
E. coli by cold-atmospheric plasma using a porcine skin model in vitro. PLoS One. 2012; 7(4):e34610.
Epub 2012/05/05. 10.1371/journal.pone.0034610 PMID: 22558091; PubMed Central PMCID:
PMC3338731.
20. Hu¨fner A, Steffen H., Holtfreter B., Schlu¨ter R., Duske K., Matthes R., von Woedtke T., Weltmann K.,
Kocher T. and Jablonowski L. Effects of Non-Thermal Atmospheric Pressure Plasma and Sodium
Hypochlorite Solution on Enterococcus faecalis Biofilm: An Investigation in Extracted Teeth. Wiley
Online Library. 2017. 10.1002/ppap.201600064
21. Brun P, Brun P, Vono M, Venier P, Tarricone E, Deligianni V, et al. Disinfection of ocular cells and tis-
sues by atmospheric-pressure cold plasma. PLoS One. 2012; 7(3):e33245. Epub 2012/03/21. 10.1371/
journal.pone.0033245 PMID: 22432007; PubMed Central PMCID: PMC3303808.
22. Isbary G, Morfill G, Schmidt HU, Georgi M, Ramrath K, Heinlin J, et al. A first prospective randomized
controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in
patients. Br J Dermatol. 2010; 163(1):78–82. Epub 2010/03/13. 10.1111/j.1365-2133.2010.09744.x
PMID: 20222930.
23. Rehman MU, Jawaid P, Uchiyama H, Kondo T. Comparison of free radicals formation induced by cold
atmospheric plasma, ultrasound, and ionizing radiation. Arch Biochem Biophys. 2016; 605:19–25.
Epub 2016/04/18. 10.1016/j.abb.2016.04.005 PMID: 27085689.
CAP against E. faecalis in vitro
PLOS ONE | https://doi.org/10.1371/journal.pone.0223925 November 26, 2019 12 / 15
24. Li Y, Sun K, Ye G, Liang Y, Pan H, Wang G, et al. Evaluation of Cold Plasma Treatment and Safety in
Disinfecting 3-week Root Canal Enterococcus faecalis Biofilm In Vitro. J Endod. 2015; 41(8):1325–30.
Epub 2015/06/02. 10.1016/j.joen.2014.10.020 PMID: 26027875.
25. Mai-Prochnow A, Clauson M, Hong J, Murphy AB. Gram positive and Gram negative bacteria differ in
their sensitivity to cold plasma. Sci Rep. 2016; 6:38610. Epub 2016/12/10. 10.1038/srep38610 PMID:
27934958; PubMed Central PMCID: PMC5146927.
26. Ziuzina D, Han L, Cullen PJ, Bourke P. Cold plasma inactivation of internalised bacteria and biofilms for
Salmonella enterica serovar Typhimurium, Listeria monocytogenes and Escherichia coli. Int J Food
Microbiol. 2015; 210:53–61. Epub 2015/06/22. 10.1016/j.ijfoodmicro.2015.05.019 PMID: 26093991.
27. Rupf S, Idlibi AN, Marrawi FA, Hannig M, Schubert A, von Mueller L, et al. Removing biofilms from
microstructured titanium ex vivo: a novel approach using atmospheric plasma technology. PLoS One.
2011; 6(10):e25893. Epub 2011/10/22. 10.1371/journal.pone.0025893 PMID: 22016784; PubMed Cen-
tral PMCID: PMC3189945.
28. Habib M, Hottel T., & Hong L. Antimicrobial effects of non-thermal atmospheric plasma as a novel root
canal disinfectant. 2014. 10.1016/j.cpme.2014.07.002
29. Maisch T, Shimizu T, Mitra A, Heinlin J, Karrer S, Li YF, et al. Contact-free cold atmospheric plasma
treatment of Deinococcus radiodurans. J Ind Microbiol Biotechnol. 2012; 39(9):1367–75. Epub 2012/
05/16. 10.1007/s10295-012-1137-6 PMID: 22584820.
30. Battista JR, Earl AM, Park MJ. Why is Deinococcus radiodurans so resistant to ionizing radiation?
Trends Microbiol. 1999; 7(9):362–5. Epub 1999/09/02. 10.1016/s0966-842x(99)01566-8 PMID:
10470044.
31. Almeida A, Shao Y. Genome watch: Keeping tally in the microbiome. Nat Rev Microbiol. 2018; 16
(3):124. Epub 2018/01/31. 10.1038/nrmicro.2018.13 PMID: 29379216.
32. Shimizu T, Lachner V, Zimmermann JL. Surface Microdischarge Plasma for Disinfection. 2017; 7
(2):175–85. 10.1615/PlasmaMed.2017019455
33. Cieplik F, Pummer A, Regensburger J, Hiller KA, Spath A, Tabenski L, et al. The impact of absorbed
photons on antimicrobial photodynamic efficacy. Front Microbiol. 2015; 6:706. Epub 2015/08/04. 10.
3389/fmicb.2015.00706 PMID: 26236292; PubMed Central PMCID: PMC4502582.
34. Cieplik F, Spath A, Regensburger J, Gollmer A, Tabenski L, Hiller KA, et al. Photodynamic biofilm inacti-
vation by SAPYR—an exclusive singlet oxygen photosensitizer. Free Radic Biol Med. 2013; 65:477–
87. Epub 2013/07/31. 10.1016/j.freeradbiomed.2013.07.031 PMID: 23891675.
35. Pratten J, Wills K, Barnett P, Wilson M. In vitro studies of the effect of antiseptic-containing mouth-
washes on the formation and viability of Streptococcus sanguis biofilms. J Appl Microbiol. 1998; 84
(6):1149–55. Epub 1998/08/26. 10.1046/j.1365-2672.1998.00462.x PMID: 9717301.
36. Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. J Hyg (Lond). 1938;
38(6):732–49. Epub 1938/11/01. 10.1017/s002217240001158x PMID: 20475467; PubMed Central
PMCID: PMC2199673.
37. Cieplik F, Steinwachs VS, Muehler D, Hiller KA, Thurnheer T, Belibasakis GN, et al. Phenalen-1-one-
Mediated Antimicrobial Photodynamic Therapy: Antimicrobial Efficacy in a Periodontal Biofilm Model
and Flow Cytometric Evaluation of Cytoplasmic Membrane Damage. Front Microbiol. 2018; 9:688.
Epub 2018/04/24. 10.3389/fmicb.2018.00688 PMID: 29681899; PubMed Central PMCID:
PMC5897782.
38. Chen CZ, Cooper SL. Interactions between dendrimer biocides and bacterial membranes. Biomaterials.
2002; 23(16):3359–68. Epub 2002/07/09. 10.1016/s0142-9612(02)00036-4 PMID: 12099278.
39. Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the
Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand
Hygiene Task Force. Infect Control Hosp Epidemiol. 2002; 23(12 Suppl):S3–40. Epub 2003/01/08. 10.
1086/503164 PMID: 12515399.
40. Kollmuss M, Kist S, Obermeier K, Pelka AK, Hickel R, Huth KC. Antimicrobial effect of gaseous and
aqueous ozone on caries pathogen microorganisms grown in biofilms. Am J Dent. 2014; 27(3):134–8.
Epub 2014/09/12. PMID: 25208360.
41. Walters J. How antibiotics work: protein synthesis. Prof Nurse. 1993; 8(12):788–91. Epub 1993/09/01.
PMID: 8367507.
42. Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: A guide for clini-
cians. J Anaesthesiol Clin Pharmacol. 2017; 33(3):300–5. Epub 2017/11/08. 10.4103/joacp.JOACP_
349_15 PMID: 29109626; PubMed Central PMCID: PMC5672523.
43. Becker S, Zimmermann JL, Baumeister P, Brunner TF, Shimizu T, Li YF, et al. Effects of cold atmo-
spheric plasma (CAP) on bacteria and mucosa of the upper aerodigestive tract. Auris Nasus Larynx.
2019; 46(2):294–301. Epub 2018/08/14. 10.1016/j.anl.2018.07.008 PMID: 30098846.
CAP against E. faecalis in vitro
PLOS ONE | https://doi.org/10.1371/journal.pone.0223925 November 26, 2019 13 / 15
44. Lis KA, Boulaaba A, Binder S, Li Y, Kehrenberg C, Zimmermann JL, et al. Inactivation of Salmonella
Typhimurium and Listeria monocytogenes on ham with nonthermal atmospheric pressure plasma.
PLoS One. 2018; 13(5):e0197773. Epub 2018/05/26. 10.1371/journal.pone.0197773 PMID: 29795627;
PubMed Central PMCID: PMC5967798 GmbH. The scientific cooperation with Drs Zimmermann and Li
with TiHo-Hannover dates back to the time when they were both employed at the Max Planck Institute
for extraterrestrial Physics. Since their appointments at terraplasma GmbH (a spin-out start-up from the
Max Planck Society) they have been given freedom to carry on with the basic research that was started
earlier and is continuing. Their contribution to the current paper has been scientific—involving study
design, analysis and interpretation and preparation of the manuscript. Ms Binder is a Bio-Engineer and
helped in preparing the specialized plasma equipment used in the research and optimizing it for bacteri-
cidal and virucidal effects, without which the success of the study would not have been possible. The
specialized plasma source was designed and manufactured at terraplasma and sold at cost price to
TiHo-Hannover. terraplasma GmbH made no financial contribution other than continuing salary pay-
ments for (JZ, SyB and YFL). There are no further patents, products in development or marketed prod-
ucts to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and
materials, as detailed online in the guide for authors.
45. Wende K, Bekeschus S, Schmidt A, Jatsch L, Hasse S, Weltmann KD, et al. Risk assessment of a cold
argon plasma jet in respect to its mutagenicity. Mutat Res Genet Toxicol Environ Mutagen. 2016;798–
799:48–54. Epub 2016/03/21. 10.1016/j.mrgentox.2016.02.003 PMID: 26994493.
46. Yang Y, Guo J, Zhou X, Liu Z, Wang C, Wang K, et al. A novel cold atmospheric pressure air plasma jet
for peri-implantitis treatment: An in vitro study. Dent Mater J. 2018; 37(1):157–66. Epub 2017/11/28. 10.
4012/dmj.2017-030 PMID: 29176301.
47. Weiss M, Barz J, Ackermann M, Utz R, Ghoul A, Weltmann KD, et al. Dose-Dependent Tissue-Level
Characterization of a Medical Atmospheric Pressure Argon Plasma Jet. ACS Appl Mater Interfaces.
2019; 11(22):19841–53. Epub 2019/05/10. 10.1021/acsami.9b04803 PMID: 31071258.
48. Gan L, Zhang S, Poorun D, Liu D, Lu X, He M, et al. Medical applications of nonthermal atmospheric
pressure plasma in dermatology. J Dtsch Dermatol Ges. 2018; 16(1):7–13. Epub 2017/12/07. 10.1111/
ddg.13373 PMID: 29211323.
49. Joaquin JC, Kwan C, Abramzon N, Vandervoort K, Brelles-Marino G. Is gas-discharge plasma a new
solution to the old problem of biofilm inactivation? Microbiology. 2009; 155(Pt 3):724–32. Epub 2009/
02/28. 10.1099/mic.0.021501-0 PMID: 19246743.
50. Laroussi M. Nonthermal decontamination of biological media by atmospheric-pressure plasmas:
review, analysis, and prospects. IEEE Transactions on Plasma Science. 2002; 30. 10.1109/TPS.2002.
804220
51. Dezest M, Bulteau AL, Quinton D, Chavatte L, Le Bechec M, Cambus JP, et al. Oxidative modification
and electrochemical inactivation of Escherichia coli upon cold atmospheric pressure plasma exposure.
PLoS One. 2017; 12(3):e0173618. Epub 2017/03/31. 10.1371/journal.pone.0173618 PMID: 28358809;
PubMed Central PMCID: PMC5373509.
52. Ziuzina D, Boehm D, Patil S, Cullen PJ, Bourke P. Cold Plasma Inactivation of Bacterial Biofilms and
Reduction of Quorum Sensing Regulated Virulence Factors. PLoS One. 2015; 10(9):e0138209. Epub
2015/09/22. 10.1371/journal.pone.0138209 PMID: 26390435; PubMed Central PMCID: PMC4577073.
53. Ureyen Kaya B, Kececi AD, Guldas HE, Cetin ES, Ozturk T, Oksuz L, et al. Efficacy of endodontic appli-
cations of ozone and low-temperature atmospheric pressure plasma on root canals infected with
Enterococcus faecalis. Lett Appl Microbiol. 2014; 58(1):8–15. Epub 2013/08/29. 10.1111/lam.12148
PMID: 23980743.
54. Jiang C, Schaudinn C, Jaramillo DE, Webster P, Costerton JW. In Vitro Antimicrobial Effect of a Cold
Plasma Jet against Enterococcus faecalis Biofilms. ISRN Dent. 2012; 2012:295736. Epub 2012/03/31.
10.5402/2012/295736 PMID: 22461988; PubMed Central PMCID: PMC3302053.
55. Modic M, McLeod NP, Sutton JM, Walsh JL. Cold atmospheric pressure plasma elimination of clinically
important single- and mixed-species biofilms. Int J Antimicrob Agents. 2017; 49(3):375–8. Epub 2017/
02/06. 10.1016/j.ijantimicag.2016.11.022 PMID: 28161488.
56. Lis KA, Kehrenberg C, Boulaaba A, von Kockritz-Blickwede M, Binder S, Li Y, et al. Inactivation of multi-
drug-resistant pathogens and Yersinia enterocolitica with cold atmospheric-pressure plasma on stain-
less-steel surfaces. Int J Antimicrob Agents. 2018; 52(6):811–8. Epub 2018/09/04. 10.1016/j.
ijantimicag.2018.08.023 PMID: 30176354.
57. Flynn PB, Higginbotham S, Alshraiedeh NH, Gorman SP, Graham WG, Gilmore BF. Bactericidal effi-
cacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens. Int J Anti-
microb Agents. 2015; 46(1):101–7. Epub 2015/05/13. 10.1016/j.ijantimicag.2015.02.026 PMID:
25963338.
CAP against E. faecalis in vitro
PLOS ONE | https://doi.org/10.1371/journal.pone.0223925 November 26, 2019 14 / 15
58. Ballout H, Hertel M, Doehring J, Kostka E, Hartwig S, Paris S, et al. Effects of plasma jet, dielectric bar-
rier discharge, photodynamic therapy and sodium hypochlorite on infected curved root canals. J Bio-
photonics. 2018; 11(3). Epub 2017/10/13. 10.1002/jbio.201700186 PMID: 29024574.
59. Armand A, Khani M, Asnaashari M, AliAhmadi A, Shokri B. Comparison study of root canal disinfection
by cold plasma jet and photodynamic therapy. Photodiagnosis Photodyn Ther. 2019. Epub 2019/04/27.
10.1016/j.pdpdt.2019.04.023 PMID: 31026615.
60. Du TF, Tang XZ, Shi Q, Gan K, Zhu JF, Cao YG. [Killing activity of nonequilibrium plasma against
young and old Enterococcus faecalis biofilms with long-term exposure in infected root canals in vitro].
Zhonghua Kou Qiang Yi Xue Za Zhi. 2018; 53(10):681–7. Epub 2018/11/06. 10.3760/cma.j.issn.1002-
0098.2018.10.007 PMID: 30392225.
61. Boxhammer V, Li YF, Koritzer J, Shimizu T, Maisch T, Thomas HM, et al. Investigation of the mutagenic
potential of cold atmospheric plasma at bactericidal dosages. Mutat Res. 2013; 753(1):23–8. Epub
2013/02/19. 10.1016/j.mrgentox.2012.12.015 PMID: 23416235.
62. Maisch T, Bosserhoff AK, Unger P, Heider J, Shimizu T, Zimmermann JL, et al. Investigation of toxicity
and mutagenicity of cold atmospheric argon plasma. Environ Mol Mutagen. 2017; 58(3):172–7. Epub
2017/04/04. 10.1002/em.22086 PMID: 28370324.
63. Herbst SR, Hertel M, Ballout H, Pierdzioch P, Weltmann KD, Wirtz HC, et al. Bactericidal Efficacy of
Cold Plasma at Different Depths of Infected Root Canals In Vitro. Open Dent J. 2015; 9:486–91. Epub
2015/01/01. 10.2174/1874210601509010486 PMID: 26962378; PubMed Central PMCID:
PMC4768658.
64. Han L, Patil S, Boehm D, Milosavljevic V, Cullen PJ, Bourke P. Mechanisms of Inactivation by High-
Voltage Atmospheric Cold Plasma Differ for Escherichia coli and Staphylococcus aureus. Appl Environ
Microbiol. 2016; 82(2):450–8. Epub 2015/11/01. 10.1128/AEM.02660-15 PMID: 26519396; PubMed
Central PMCID: PMC4711144.
65. Zahradka K, Slade D, Bailone A, Sommer S, Averbeck D, Petranovic M, et al. Reassembly of shattered
chromosomes in Deinococcus radiodurans. Nature. 2006; 443(7111):569–73. Epub 2006/09/29. 10.
1038/nature05160 PMID: 17006450.
66. Cox MM, Battista JR. Deinococcus radiodurans—the consummate survivor. Nat Rev Microbiol. 2005; 3
(11):882–92. Epub 2005/11/02. 10.1038/nrmicro1264 PMID: 16261171.
67. Arjunan KP, Sharma VK, Ptasinska S. Effects of atmospheric pressure plasmas on isolated and cellular
DNA-a review. Int J Mol Sci. 2015; 16(2):2971–3016. Epub 2015/02/03. 10.3390/ijms16022971 PMID:
25642755; PubMed Central PMCID: PMC4346876.
CAP against E. faecalis in vitro
PLOS ONE | https://doi.org/10.1371/journal.pone.0223925 November 26, 2019 15 / 15
